Acetaminophen Dexbrompheniramine

證據等級: L5

預測適應症: 0 個

Acetaminophen + Dexbrompheniramine: From Cold & Allergy Relief to [No TxGNN Predictions Available]

One-Sentence Summary

Acetaminophen is a widely used analgesic and antipyretic; dexbrompheniramine is a first-generation H1 antihistamine. Together, this fixed-dose combination is typically used to relieve symptoms of the common cold and seasonal allergies (e.g., runny nose, sneezing, minor aches, and fever).

The TxGNN model returned no predicted new indications for this combination, and the drug is not currently marketed in the United States. Without active TxGNN predictions and with multiple blocking data gaps, a formal repurposing analysis cannot be completed at this stage.

Quick Overview

Item	Content
Original Indication	Cold & allergy symptom relief (analgesic + antihistamine combination; not formally recorded in this Evidence Pack)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (no predictions, no supporting studies identified)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN repurposing prediction was generated for this drug combination. Therefore, a mechanism-based justification for a new indication cannot be provided at this time.

For reference, the two components have distinct pharmacological profiles:

Acetaminophen acts centrally to inhibit prostaglandin synthesis and modulate descending serotonergic pain pathways. It is one of the most broadly used analgesics and antipyretics globally.
Dexbrompheniramine is the active dextrorotatory enantiomer of brompheniramine and competitively blocks peripheral H1 histamine receptors, reducing allergic and cold-related symptoms such as rhinorrhea and sneezing.

Currently, detailed mechanism of action data is not available from this Evidence Pack. To support a future repurposing hypothesis for this combination, DrugBank API data (remediation flagged as DG002) should be retrieved to populate the full MOA profile.

Clinical Trial Evidence

Currently no related clinical trials registered for this combination as a repurposing candidate.

Literature Evidence

Currently no related literature available for this combination as a repurposing candidate.

US Market Information

This drug combination holds no US NDA approvals on record in this Evidence Pack. It is classified as not marketed in the United States.

Note: Individual components (acetaminophen and dexbrompheniramine) are available in various OTC products in the US (e.g., Dimetapp Cold & Allergy, Alka-Seltzer Plus), but the specific combination as a fixed-dose prescription or OTC product has no documented NDA entry in this dataset.

Safety Considerations

Please refer to the package insert for safety information.

The Evidence Pack contains no safety data for this combination. Two data gaps have been flagged as requiring remediation before safety assessment can proceed:

DG001 (Blocking) — TFDA prescribing information (warnings/contraindications) has not been retrieved. This must be resolved before the S1 safety screen can be initiated.

DG002 (High) — Mechanism of action data from DrugBank is missing, which limits mechanistic risk assessment.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model produced no repurposing predictions for this combination, and both critical safety and MOA data are absent. There is currently no actionable signal to evaluate.

To proceed, the following is needed:

Resolve DG001 (Blocking): Download and parse the TFDA package insert PDF to populate warnings and contraindications — this is required before any safety screen.
Resolve DG002 (High): Query the DrugBank API for both acetaminophen and dexbrompheniramine to retrieve full MOA data, enabling mechanistic analysis.
Re-run TxGNN prediction: Verify whether the query was submitted correctly (the drug INN contains a semicolon separator — confirm the pipeline correctly handles combination drug entries). If the combination was not recognized as a valid entity, query each component individually.
Confirm drug identity: The drugbank_id field is null; map each component to its respective DrugBank ID (e.g., acetaminophen → DB00316, dexbrompheniramine → DB01246) to enable downstream evidence collection.
Once the above steps are complete, re-generate the Evidence Pack and re-evaluate.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.